A phase Ib/II clinical evaluation of the safety and tolerability of maintenance 5-Azacitidine combined with Lenalidomide in patients in complete remission after cytoreductive chemotherapy for acute myeloid leukaemia (AML).

Trial Profile

A phase Ib/II clinical evaluation of the safety and tolerability of maintenance 5-Azacitidine combined with Lenalidomide in patients in complete remission after cytoreductive chemotherapy for acute myeloid leukaemia (AML).

Completed
Phase of Trial: Phase I/II

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Acronyms REV-AZA
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 24 Mar 2017 Status changed from recruiting to completed.
    • 08 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top